RxDoctor Payments Data

Infanta Stephen, MD

Neurology · Dover, NJNPI 1114019072

Payments from drug & device makers

$3,759in general payments, 2019–2025

Across 170 payments — averaging $22.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Banner Life Sciences, LLC$900
  • AbbVie$651
  • Novartis$467
  • Lilly USA, LLC$232
  • Biogen$222
  • Amneal Pharmaceuticals LLC$177
  • plus $1K from 19 others

What the payments were for

  • Speaking & faculty fees$90024%
  • Food & beverage$2,78374%
  • Education$762%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,759 in reported general payments places this provider in the 55th percentile of 521 neurology providers in New Jersey.

See all neurology providers in New Jersey

Medicare billing

Part B allowed, 2024
$163,608
Medicare patients
470
Services billed
1,072

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate16$116,058
Gamunex-CImmune Globul G/Gly/Iga Avg 4613$96,501
NamzaricMemantine Hcl/Donepezil Hcl22$28,394
RexultiBrexpiprazole15$28,120
Aimovig AutoinjectorErenumab-Aooe18$26,649
Lacosamide131$17,143
Memantine Hcl279$11,960
Carbamazepine ErCarbamazepine58$7,591
Levetiracetam275$6,711
Entacapone24$6,002
Carbidopa-LevodopaCarbidopa/Levodopa208$5,912
DilantinPhenytoin Sodium Extended23$5,877
Oxcarbazepine56$5,007
Primidone135$4,172
Donepezil Hcl337$3,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$45$96,50113 claims
AbbVieNamzaric$651$28,39422 claims
Otsuka America Pharmaceutical, Inc.Rexulti$40$28,12015 claims
PfizerDilantin$59$5,87723 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$177$98821 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 521 neurology providers in New Jersey.

Other neurology in Dover

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →